PHocus: a global Phase 2 study of inhaled mosliciguat in pulmonary hypertension associated with interstitial lung disease (PH-ILD)
Hossein Ardeschir Ghofrani(Justus-Liebig-Universität Gießen), Marc Humbert(Inserm), Rajan Saggar(Los Angeles Medical Center), Rogério Souza(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Jean-Luc Vachiéry(Erasmus Hospital), Ubaldo J. Martin(AstraZeneca (Japan)), Sudhir Penugonda(ClearMotion (United States)), Jennifer Cormier(ClearMotion (United States)), Allison Widlitz(ClearMotion (United States)), Laura Price(Harefield Hospital), Vincent Cottin(Université Claude Bernard Lyon 1), Carlos Sanmarco(ClearMotion (United States)), Aaron Waxman(Brigham and Women's Hospital)
Cited by 0
Related Papers
An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias
|American Journal of Respiratory and Critical Care Medicine|2013|4.3k
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline
|American Journal of Respiratory and Critical Care Medicine|2018|4.1k
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
|New England Journal of Medicine|2019|2.3k
Inhaled Iloprost for Severe Pulmonary Hypertension
|New England Journal of Medicine|2002|1.8k